Hyperion rises 13.4% on Ravicti data publication
This article was originally published in Scrip
Executive Summary
Hyperion Therapeutics ended the day at a new high on 25 February, gaining 13.4% to close at $31.41 per share based on newly published data for Ravicti (glycerol phenylbutyrate) in the treatment of hepatic encephalopathy (HE) and the company's Phase III update.